Previous 10 | Next 10 |
SELLAS Life Sciences (NASDAQ: SLS ) has started patient screening for its Phase 3 REGAL clinical trial of its lead clinical candidate, galinpepimut-S (GPS), in patients with acute myeloid leukemia (AML) who have achieved complete remission after second-line anti-leukemic therapy (CR2). M...
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicati...
SELLAS Life Sciences Group, Inc. (SLS) 12th Annual LD Micro Main Event Conference Call December 11, 2019 12:00 PM ET Company Participants Angelos Stergiou - President and Chief Executive Officer Conference Call Participants Presentation Angelos Stergiou Good morning, ev...
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicati...
ChemoCentryx (NASDAQ: CCXI ) +323% on positive test results . More news on: ChemoCentryx, Inc., Nutanix, Inc., InflaRx N.V., Stocks on the move, Read more ...
Gainers: Karuna Therapeutics (NASDAQ: KRTX ) +282% More news on: Karuna Therapeutics, Inc., Hermitage Offshore Services Ltd., Eltek Ltd., Stocks on the move, Read more ...
SELLAS Life Sciences (NASDAQ: SLS ) -21% . More news on: SELLAS Life Sciences Group, Inc., Senmiao Technology Limited, Qudian Inc., Stocks on the move, Read more ...
SELLAS Life Sciences (NASDAQ: SLS ): Q3 GAAP EPS of -$2.68 misses by $1.68 . More news on: SELLAS Life Sciences Group, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to Support the Development of GPS in Combination with a PD-1 Inhibitor in Ovarian Cancer - ...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...